Laëtitia A.
- Country
- France
- Department
- Department of Urology/ Oncology
Research Overview
- Phase III Evaluation of Acetylsalicylic Acid and Atorvastatin on Overall Survival in Castration-Resistant Prostate Cancer Patients
- Evaluation of Therapeutic De-escalation in HER2-Positive Metastatic Breast Cancer Using Trastuzumab and Drug Combination in Patients with Controlled Disease
- PEACE-6 Poor Responders: A randomized phase III trial evaluating the efficacy and safety of 177Lu-PSMA-617 in addition to Standard of Care (SoC) versus SoC alone in de novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC.
Data & Insights
Has run more than one trial at 65 of 220 partner sites.
Specializations
Prostate Cancer Research
This investigator specializes in treating advanced forms of metastatic prostate cancer, with particular focus on radiopharmaceutical therapies. Their expertise extends to managing cases of hormone-sensitive prostate cancer (mHSPC) and castration-resistant prostate cancer (mCRPC).
- 177Lu-PSMA therapy applications
- Advanced treatment protocols for metastatic disease
- Therapeutic management of treatment-resistant cases
Their work encompasses innovative approaches in prostate cancer treatment, particularly focusing on patients who show limited response to conventional therapies.
Breast Cancer Innovation
The investigator conducts research in HER2-positive breast cancer treatment optimization, specifically focusing on metastatic breast cancer management. Their work involves evaluating treatment de-escalation strategies in carefully selected patients.
- HER2-targeted therapy optimization
- Blood-based cancer monitoring
- Maintenance treatment strategies
The research explores personalized approaches to treatment duration based on molecular response monitoring.
Precision Oncology
This investigator focuses on targeted therapy approaches for patients with solid tumors harboring specific genetic alterations. Their expertise includes the treatment of cancers with FGFR gene alterations.
- Molecular-guided cancer therapy
- FGFR inhibitor treatment
- Recurrent and metastatic cancer management
Their research emphasizes personalized treatment strategies based on specific genetic markers in various cancer types.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.